Research programme: small molecule therapeutics - Jubilant Biosys/Sanofi
Latest Information Update: 28 Mar 2023
At a glance
- Originator Jubilant Biosys; Sanofi
- Class Neuroprotectants; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for research development in Neurological-disorders in India
- 13 Feb 2019 Jubilant Biosys and Sanofi agree to discover small molecule therapeutics in India for Neurological disorders
- 13 Feb 2019 Early research in Neurological disorders in India (unspecified route)